You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Profile for Taiwan Patent: I540128


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Taiwan Patent: I540128

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Mar 25, 2028 Novartis TASIGNA nilotinib hydrochloride
⤷  Get Started Free Jan 18, 2027 Novartis TASIGNA nilotinib hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of Taiwan Patent TWI540128: Scope, Claims, and Patent Landscape

Last updated: August 1, 2025

Introduction

Taiwan Patent TWI540128 pertains to a pharmaceutical invention, the specifics of which are embedded within its patent claims. Understanding its scope and positioning within the patent landscape is crucial for stakeholders—including pharmaceutical innovators, generic manufacturers, and legal entities—in assessing potential infringement risks, licensing opportunities, and competitive intelligence. This analysis dissects the patent's claims, interpretations, and the broader patent environment, offering clarity on its enforceability and strategic implications.


1. Patent Overview and Filing Details

Patent TWI540128 was filed with the Taiwan Intellectual Property Office (TIPO). While the full text isn't provided here, such patents typically encompass detailed descriptions, claims defining the scope, and drawings illustrating the invention. The patent number indicates its registration in Taiwan’s jurisdiction, which generally provides a 20-year term from the filing date, subject to maintenance fees.

Filing and Priority Context:
This patent generally follows Taiwan's patent laws, aligning with international standards such as the Patent Cooperation Treaty (PCT) and the Paris Convention. Its priority date marks the critical date for establishing novelty and inventive step over existing art.


2. Claim Construction and Scope

2.1. Claims Overview

The core of the patent’s legal enforceability resides in its claims. These define the extent of the patent’s protection.

  • Independent Claims: Typically, these lay out the broadest scope—defining the core invention, such as a novel compound, formulation, method of manufacture, or therapeutic use.

  • Dependent Claims: These refine the independent claims, adding specific limitations such as dosage, formulation details, or particular implementations.

2.2. Likely Structure and Focus

Based on industry standards for pharmaceutical patents, TWI540128 likely involves:

  • Chemical Compound Claims: Covering a novel active pharmaceutical ingredient (API) or a novel chemical derivative.

  • Formulation Claims: Encompassing specific drug delivery systems, excipient combinations, or sustained-release formulations.

  • Method Claims: Covering novel processes for manufacturing the API or formulation.

  • Use Claims: Possible patenting of a specific therapeutic indication.

2.3. Claim Scope Analysis

The scope hinges on:

  • Broadness of the claims: Wide claims covering a new chemical class or narrow claims specific to a compound's stereochemistry or formulation.

  • Language used: Use of terms like “comprising,” “consisting of,” or “configured to” impacts broadness.

  • Claim dependencies: Dependent claims add specificity that may narrow enforcement but strengthen the patent’s defensibility.

Implication:
A patent with broad claims offers extensive protection but requires robust novelty and inventive step arguments. Narrow claims might be easier to defend but could be easier for competitors to design around.


3. Patent Landscape Analysis

3.1. Key Patent Families and Related Art

In the pharmaceutical patent arena, numerous patent families cover similar or related compounds and methods, often resulting in a dense landscape.

  • Global Patent Publications: TWI540128 may overlap with patents worldwide, especially in jurisdictions such as the US, China, and Europe, given Taiwan’s strategic position as a manufacturing hub.

  • Prior Art and Overlaps: Patents on similar chemical entities, formulations, or therapeutic uses could impact TWI540128’s validity and enforcement. For example, prior publications describing similar compounds or methods could serve as prior art challenging its novelty.

3.2. Competitive Landscape

  • Active Patent Holders: Major pharmaceutical companies often secure patents like TWI540128 for new compounds or formulations, positioning themselves for market exclusivity.

  • Freedom-to-Operate (FTO): A comprehensive FTO analysis would require comparing claims with existing patents. If similar patents exist, licensing or design-around strategies may be necessary.

  • Patent Thickets: The existence of multiple overlapping patents may complicate commercialization efforts, requiring careful navigation of licensing agreements.

3.3. Patent Filings and Trends

  • Research & Development Trends: If TWI540128 relates to a class of biologics or small molecules, adjacent patents may be emerging in these areas.

  • Lifecycle Management: Post-grant strategies may include filing divisional or continuation applications to extend protection or fortify patent estate.


4. Patent Validity and Enforceability Factors

  • Novelty: The invention must be distinct from prior art at the filing date.

  • Inventive Step: The invention must demonstrate non-obviousness over existing knowledge.

  • Industrial Applicability: It must be capable of practical application, which is generally straightforward for pharmaceutical inventions.

  • Patent Examination: TIPO’s examination process reviews these criteria, but potential challenges can arise, especially regarding the novelty of chemical compounds or methods.


5. Strategic Considerations

  • Licensing Opportunities: Firms interested in the protected compound, process, or use might seek license agreements.

  • Infringement Risks: Competitors developing similar compounds or formulations must assess patent claims thoroughly.

  • Patent Enforcement: Enforcers should focus on the patent’s broadest claims, especially if they cover a core active ingredient or therapeutic application.

  • Patent Expiry: In 20 years from filing, the patent represents a significant exclusivity period, but competitors may challenge validity or develop novel alternatives.


6. Conclusion and Forward-Looking Insights

Patent TWI540128 grants potentially broad protection for a specific pharmaceutical invention, likely a novel compound or formulation. Its scope encompasses chemical, formulation, and possibly method claims, fitting into the strategic patent landscape in Taiwan and globally. Stakeholders must engage in meticulous validity and infringement analyses, considering existing patents and the evolving patent landscape.


Key Takeaways

  • Scope Clarity: The patent’s enforceability hinges on well-defined claims. Broad independent claims offer wider protection but face higher validity scrutiny.

  • Landscape Positioning: TWI540128 exists within a competitive patent environment. Understanding overlapping patents is critical for strategic planning.

  • Validity and Enforcement: Ensuring the patent maintains novelty and inventive step is vital, especially against prior art doubts.

  • Lifecycle & Expansion: Consider filing divisional or continuation applications for extending patent life or covering additional indications or formulations.

  • Strategic Use: The patent provides a foundation for licensing, collaboration, or defending against generic challenges in Taiwan and potentially other jurisdictions.


FAQs

  1. What types of claims are most common in pharmaceutical patents like TWI540128?
    Typically, pharmaceutical patents include claims on chemical compounds, formulations, methods of manufacturing, and therapeutic uses, often grouped into broad independent claims and more specific dependent claims.

  2. How does Taiwan’s patent law influence the scope of TWI540128?
    Taiwan adopts standards aligned with international patent law, requiring novelty, inventive step, and industrial applicability. These standards influence claim breadth and validity considerations.

  3. Can existing patents challenge the validity of TWI540128?
    Yes, if prior art documents disclose similar compounds, methods, or uses, challengers can petition for patent revocation based on lack of novelty or inventive step.

  4. What strategic actions should patent holders take after establishing TWI540128?
    They should monitor competitors, consider patent family expansions, enforce rights against infringers, and evaluate licensing opportunities.

  5. Is TWI540128 likely to be enforceable against generic competitors in Taiwan?
    If the claims are valid and infringement is established, enforceability is high, enabling the patent holder to block or negotiate licensing with generics.


References

  1. Taiwan Intellectual Property Office (TIPO). Patent Application Specifications and Examination Guidelines.
  2. World Intellectual Property Organization (WIPO). Patent Searching Tools and Strategies for Pharmaceutical Patents.
  3. European Patent Office (EPO). Patentability Criteria for Chemical and Pharmaceutical Inventions.
  4. United States Patent and Trademark Office (USPTO). Patent Examination Guidelines.
  5. PatentScope. Global Patent Landscape and Pharmaceutical Patent Trends.

[Please note: For full assessment, detailed patent claims, and specific legal status, access to the official patent documents and legal databases is recommended.]

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.